CSB 2.009 Note(o) Zaleplon.
CSB 2.009 Note(p) Zolpidem.
CSB 2.009 Note(at) Fenproporex.
CSB 2.009 Note(bu) Modafinil.
CSB 2.009 Note(f) Sibutramine.
CSB 2.009 HistoryHistory: Cr. Register, July, 2000, No. 535, eff. 8-1-00. CSB 2.009 NoteCSB 2.26 Addition of dihydroetorphine to schedule II. (1) Section 961.16 (2) (a) 4r., Stats., is created to read: CSB 2.009 Note4r. Dihydroetorphine.
CSB 2.009 HistoryHistory: CR 01-071: Cr. Register November 2001 No. 551, eff. 12-1-01. CSB 2.009 NoteCSB 2.28 Addition of dichloralphenazone to schedule IV. (1) Section 961.20 (2) (cs), Stats., is created to read: CSB 2.009 HistoryHistory: CR 02-025: Cr. Register October 2002 No. 562, eff. 11-1-02. CSB 2.009 NoteCSB 2.29 Transfer of buprenorphine from schedule V to schedule III. (1) Section 961.18 (5m), Stats., is created to read: CSB 2.009 NoteSection 961.18 (5m) Narcotic Drugs Not Limited by Quantity. Any material, compound, mixture, or preparation containing any of the following narcotic drugs, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation: CSB 2.009 Note(a) Buprenorphine
CSB 2.009 HistoryHistory: CR 03-056: cr. Register January 2004 No. 577, eff. 2-1-04. CSB 2.009 NoteCSB 2.30 Addition of gamma-hydroxybutyric acid to schedule III. (1) Section 961.18 (3) (o), Stats., is created to read: CSB 2.009 NoteSection 961.18 (3) (o) Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal food, drug and cosmetic act: CSB 2.009 Note1. Gamma-hydroxybutyric acid.
CSB 2.009 HistoryHistory: CR 03-057: cr. Register January 2004 No. 577, eff. 2-1-04. CSB 2.009 NoteCSB 2.31 Addition of 2,5 dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7) to schedule I. (1) Section 961.14 (4) (wh), Stats., is created to read: CSB 2.009 NoteSection 961.14 (4) (wh) 2,5 dimethoxy-4-(n)- propylthiophenethylamine, commonly known as “2C-T-7”; CSB 2.009 HistoryHistory: CR 06-058: cr. Register April 2007 No. 616, eff. 5-1-07. CSB 2.009 NoteCSB 2.32 Addition of N- benzylpiperazine (BZP) to schedule I. (1) Section 961.14 (7) (q), Stats., is created to read: CSB 2.009 NoteSection 961.14 (7) (q) N- benzylpiperazine, commonly known as “BZP.” CSB 2.009 HistoryHistory: CR 06-058: cr. Register April 2007 No. 616, eff. 5-1-07. CSB 2.009 NoteCSB 2.33 Addition of alpha-methyltryptamine (AMT) to schedule I. (1) Section 961.14 (4) (wi), Stats., is created to read: CSB 2.009 NoteSection 961.14 (4) (wi) Alpha-methyltryptamine, commonly known as “AMT”; CSB 2.009 HistoryHistory: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07. CSB 2.009 NoteCSB 2.34 Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT). (1) Section 961.14 (4) (wj), Stats., is created to read: CSB 2.009 NoteSection 961.14 (4) (wj) 5-methoxy-N, N-diisopropyltryptamine, commonly known as “5-MeO-DIPT”; CSB 2.009 HistoryHistory: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07. CSB 2.009 NoteCSB 2.35 Addition of lisdexamfetamine to schedule II. (1) Section 961.16 (5) (e), Stats., is created to read: CSB 2.009 NoteSection 961.16 (5) (e) Lisdexamfetamine, commonly known as “Vyvanse TM.” CSB 2.009 HistoryHistory: CR 10-112: cr. Register April 2011 No. 664, eff. 5-1-11. CSB 2.009 NoteCSB 2.36 Addition of tramadol to schedule IV. Section 961.20 (4) (e), Stats., is created to read: CSB 2.009 NoteSection 961.20 (4) (e) Tramadol, including any of its isomers and salts of isomers. CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 968.11 (4), Stats., Register August 2014 No. 704, eff. 9-1-14; CR 15-008: cr. Register October 2015 No. 718, eff. 11-1-15. CSB 2.009 NoteCSB 2.37 Rescheduling of hydrocodone combination products. Sections 961.18 (5) (c) and (d), Stats., are repealed.
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11-1-14; CR 15-007: cr. Register October 2015 No. 718, eff. 11-1-15. CSB 2.009 NoteCSB 2.38 Addition of suvorexant to schedule IV. Section 961.20 (2) (mr), Stats., is created to read: CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11-1-14; CR 15-009: cr. Register October 2015 No. 718, eff. 11-1-15. CSB 2.009 Note961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2015 No. 711B, eff. 4-1-15; CR 15-068: cr. Register August 2016 No. 728, eff. 9-1-16. CSB 2.009 NoteCSB 2.40 Exclusion of [123I]ioflupane. Section 961.16 (2) (b), Stats., is amended to read: CSB 2.009 Note(b) Coca leaves and any salt, compound, derivative or preparation of coca leaves. Decocainized coca leaves or extractions which do not contain cocaine or ecgonine are excluded from this paragraph. [123I]Ioflupane is excluded from this paragraph. The following substances and any of their salts, esters, isomers and salts of esters and isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2015 No. 718A3, eff. 10-19-15; correction made under s. 35.17, Stats., Register October 2015 No. 718; CR 16-060: cr. Register May 2017 No. 737, eff. 6-1-17. CSB 2.009 NoteCSB 2.41 Scheduling of beta-hydroxythiofentanyl and butyryl fentanyl. Sections 961.14 (2) (eu) and (ey) are created to read: CSB 2.009 Note961.14 (2) (eu) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)
CSB 2.009 Note(ey) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2016 No. 728, eff. 7-18-16; CR 16-081: cr. Register July 2017 No. 739, eff. 8-1-17. CSB 2.009 NoteCSB 2.42 Scheduling of furanyl fentanyl. Section 961.14 (2) (ne) is created to read: CSB 2.009 Note961.14 (2) (ne) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide).
CSB 2.009 HistoryHistory: EmR1626: emerg. cr., eff. 9-1-16; CR 16-059: cr. Register May 2017 No. 737, eff. 6-1-17. CSB 2.009 NoteCSB 2.43 Addition of brivaracetam to schedule V. Section 961.22 (6), Stats., is created to read: CSB 2.009 Note961.22 (6) BRIVARACETAM. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide), including its salts, isomers or salts of isomers.
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register September 2016 No. 729, eff. 9-26-16; CR 17-009: cr. Register July 2017 No. 739, eff. 8-1-17. CSB 2.009 NoteCSB 2.44 Addition of thiafentanil to schedule II. Section 961.16 (3) (zx), Stats., is created to read: CSB 2.009 Note961.16 (3) (zx) Thiafentanil.
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2016 No. 730, eff. 10-3-16; CR 17-007: cr. Register July 2017 No. 739, eff. 8-1-17. CSB 2.009 NoteCSB 2.45 Addition of AB-FUBINACA and ADB-PINACA to schedule I. Section 961.14 (4) (tb) 32. and 33., Stats., is created to read: CSB 2.009 Note961.14 (4) (tb) 32. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as AB-FUBINACA.
33. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as ADB-PINACA.
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2016 No. 730, eff. 10-10-16; CR 17-008: cr. Register July 2017 No. 739, eff. 8-1-17. CSB 2.009 NoteCSB 2.46 Addition of acetyl fentanyl to schedule I. Section 961.14 (2) (ae), Stats., is created to read: CSB 2.009 Note961.14 (2) (ae) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide).
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11-21-16; CR 17-021: cr. Register November 2017 No. 743, eff. 12-1-17. CSB 2.009 NoteCSB 2.47 Addition of AH-7921 to schedule I. Section 961.14 (2) (aj), Stats., is created to read: CSB 2.009 Note961.14 (2) (aj) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide).
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11-21-16; CR 17-023: cr. Register November 2017 No. 743, eff. 12-1-17. CSB 2.009 NoteCSB 2.48 Addition of eluxadoline to schedule IV. Section 961.20 (4) (cm), Stats., is created to read: CSB 2.009 Note961.20 (4) (cm) Eluxadoline, including any of its isomers, and salts of isomers.
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11-21-16; CR 17-022: cr. Register November 2017 No. 743, eff. 12-1-17. CSB 2.009 NoteCSB 2.49 Addition of U-47700 to schedule I. Section 961.14 (2) (z), Stats., is created to read: CSB 2.009 Note961.14 (2) (z) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide).
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2016 No. 732, eff. 12-19-16; CR 17-020: cr. Register November 2017 No. 743, eff. 12-1-17. CSB 2.009 NoteCSB 2.50 Addition of AB-CHMINACA, AB-PINACA and THJ-2201 to schedule I. Section 961.14 (4) (tb) 34., 35., and 36., Stats., are created to read: CSB 2.009 Note961.14 (4) (tb) 34. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as AB-CHMINACA.
CSB 2.009 Note35. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as AB-PINACA).
CSB 2.009 Note36. [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone, commonly known as THJ-2201.
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2017 No. 736, eff. 3-27-17; correction in (intro.) made under s. 35.17, Stats., Register April 2017 No. 736; CR 17-085: cr. Register October 2018 No. 754, eff. 11-1-18; correction in (intro.) made under s. 35.17, Stats., Register October 2018 No. 754. CSB 2.009 NoteCSB 2.51 Addition of MAB-CHMINACA to schedule I. Section 961.14 (4) (tb) 37., Stats., is created to read: CSB 2.009 Note961.14 (4) (tb) 37. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as MAB-CHMINACA or ADB-CHMINACA.
CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2017 No. 736, eff. 3-27-17; CR 17-086: cr. Register October 2018 No. 754, eff. 11-1-18. CSB 2.009 NoteCSB 2.52 Addition of 4-MePPP and a-PBP to schedule I. Section 961.14 (7) (L) 32. and 33., Stats., is created to read: CSB 2.009 Note961.14 (7) (L) 32. 4-methyl-alpha-pyrrolidinopropiophenone, commonly known as 4-MePPP.
